AFFiRiS Announces Encouraging Long-term Data from a Series of First-in-Human Studies Using AFFITOPE® PD01A Targeting Oligomeric Alpha-synuclein in Early Parkinsons Disease Patients
•Consolidated analysis across AFF008 study series completed •Reevaluation of primary and secondary endpoints confirms safety and tolerability and immunogenicity profile…
Weiterlesen